Predictive lifestyle markers for efficacy of cancer immune checkpoint inhibitors: a commentary-Reference-Cited by-同舟云学术

Predictive lifestyle markers for efficacy of cancer immune checkpoint inhibitors: a commentary

Published:2021-02 Issue:4 Volume:17 Page:363-369
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Sillah Arthur¹²^ORCID,Tykodi Scott S³⁴⁵,Hall Evan T³⁴⁵,Thompson John A³⁴⁵,Watson Nathaniel F⁶,Lee Sylvia M³⁴⁵,Bhatia Shailender³⁴⁵,Veatch Joshua³⁴⁵,Warner Jeannie⁴,Peters Ulrike¹²,Malen Rachel C²,Silverman Allison²,Phipps Amanda I¹²

Affiliation:

1. Department of Epidemiology, University of Washington School of Public Health, Seattle, WA 98195, USA

2. Epidemiology Program, Fred Hutchinson Research Cancer Research Center, Seattle, WA 98133, USA

3. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98133, USA

4. Seattle Cancer Care Alliance, Seattle, WA 98133, USA

5. University of Washington School of Medicine, Division of Medical Oncology, Seattle, WA 98195, USA

6. University of Washington School of Medicine, Department of Neurology & University of Washington Sleep Medicine Center, Seattle, WA 98195, USA

Abstract

Lifestyle factors could plausibly modulate the host immune system, the tumor microenvironment and, hence, immune checkpoint inhibitor (ICI) response. As such, these factors should be considered in ICI studies.

Funder

Fred Hutchinson Cancer Research Center

National Institutes of Health Clinical Center

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2020-0730

Reference40 articles.

1. T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

2. US Food and Drug Administration. Highlights of prescribing information. (2020). www.accessdata.fda.gov/drugsatfda_docs/label/2018/761097s000lbl.pdf

3. Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update

4. PD-L1 expression in cancer patients receiving anti PD-1/PD-L1 antibodies: A systematic review and meta-analysis

5. DNA Damage and Repair Biomarkers of Immunotherapy Response

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Smoking is an Independent Marker of Poor Prognosis in Cutaneous Melanoma;Acta Dermato-Venereologica;2023-02-07